Sorensen G, Reddy IA, Weikop P, Graham DL, Stanwood GD, Wortwein G et al
In the interim, NICE-approved options for weight management in adults with obesity include: Orlistat (available on NHS prescription) Semaglutide 2.4 mg (Wegovy) , recommended by NICE in 2023 for use in specific patient groups (NICE technology appraisal TA875) Tirzepatide (Mounjaro) , which received NICE approval in 2024 for obesity management (NICE technology appraisal TA1026) [18] Patients seeking advice about weight management or blood pressure control should be directed to their GP in the first instance, who can assess eligibility for currently approved treatments and refer to specialist services where appropriate
Susan Orringe is a chartered antiques valuer, and carries out insurance and probate valuations, and is a loss adjuster and auctioneer with over 30 years experience based in Petersfield, Hampshire
If you use oral contraceptives, consider switching to a non-oral contraceptive method (such as an IUD, patch, or implant), or use an additional barrier method (such as condoms) for at least 4 weeks after starting semaglutide and for at least 4 weeks after each dose increase
The high prevalence of IMI highlights the significance of MOSI diagnosis during infertility workup